Company: Amgen
Posted by PCSK9Grinder_AMG · March 22, 2026
Tags: territory, general
Repatha access has improved but I want to be honest: it's still a grind.
Step therapy requirements haven't gone away as much as leadership suggests.
The cardiovascular outcomes data is excellent and most cardiologists are believers at this point, but payer PA requirements still slow everything down.
I spend a significant portion of my week on access issues and escalations rather than actual detailing.
Amgen's access team is responsive when you escalate, to their credit.
But if you're coming from a market where access isn't a constant obstacle, the PCSK9 space will feel like a different job.
Plan accordingly.
15 upvotes · 0 comments